What is Zacks Small Cap’s Forecast for MIRA FY2024 Earnings?

MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) – Stock analysts at Zacks Small Cap lowered their FY2024 earnings per share estimates for shares of MIRA Pharmaceuticals in a research note issued to investors on Tuesday, March 4th. Zacks Small Cap analyst B. Sorensen now forecasts that the company will post earnings per share of ($0.66) for the year, down from their prior forecast of ($0.60). The consensus estimate for MIRA Pharmaceuticals’ current full-year earnings is ($0.60) per share.

MIRA Pharmaceuticals Price Performance

MIRA Pharmaceuticals stock opened at $1.01 on Thursday. The stock’s fifty day moving average price is $1.16 and its two-hundred day moving average price is $1.30. MIRA Pharmaceuticals has a one year low of $0.51 and a one year high of $5.01. The firm has a market cap of $16.73 million, a PE ratio of -1.80 and a beta of 2.31.

Hedge Funds Weigh In On MIRA Pharmaceuticals

A number of hedge funds have recently added to or reduced their stakes in the stock. International Assets Investment Management LLC acquired a new stake in shares of MIRA Pharmaceuticals in the 4th quarter valued at $29,000. Two Sigma Investments LP acquired a new stake in shares of MIRA Pharmaceuticals in the 4th quarter valued at $28,000. Citadel Advisors LLC acquired a new stake in shares of MIRA Pharmaceuticals in the 4th quarter valued at $112,000. Northern Trust Corp boosted its holdings in shares of MIRA Pharmaceuticals by 50.9% in the 4th quarter. Northern Trust Corp now owns 30,362 shares of the company’s stock valued at $35,000 after purchasing an additional 10,238 shares in the last quarter. Finally, Renaissance Technologies LLC acquired a new stake in shares of MIRA Pharmaceuticals in the 4th quarter valued at $52,000. Institutional investors own 35.16% of the company’s stock.

About MIRA Pharmaceuticals

MIRA Pharmaceuticals, Inc operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder.